What was the major announcement from PYC Therapeutics (ASX:PYC) regarding its kidney program?

PYC Therapeutics has commenced the Phase 1b Multiple Ascending Dose (MAD) study for its drug candidate PYC-003, having successfully dosed the first patient. This study focuses on treating Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic condition that causes fluid-filled cysts to grow in the kidneys.

Why is the Phase 1b MAD study significant for PYC Therapeutics shareholders?

This study moves PYC-003 from single-dose safety testing to repeat-dose evaluation, which is necessary for chronic conditions like kidney disease. Beyond safety, the study will track efficacy markers including total kidney volume via MRI and urinary protein levels.

What are the key clinical catalysts to watch for PYC Therapeutics in 2026 and 2027?

Investors should monitor two major milestones: the release of Phase 1a Single Ascending Dose (SAD) data expected in the second half of 2026, and the Phase 1b MAD results slated for 2027.

How did VP-001 perform in recent clinical updates?

At the ARVO 2026 conference, PYC reported that its ophthalmology candidate VP-001 showed "clinically meaningful" improvements in visual acuity for patients with Retinitis Pigmentosa 11.

What is the current cash position of PYC Therapeutics (ASX:PYC)?

PYC Therapeutics recently bolstered its balance sheet by raising approximately $47 million through a retail entitlement offer at $1.50 per share. This capital injection is intended to fund the progression of its dual pipeline in renal and ocular diseases through these expensive clinical trial phases.

PYC Therapeutics advances kidney program with Phase 1b study

Written by Liezl GambePublished May. 7 2026Last Updated May. 7 2026

PYC Therapeutics (ASX:PYC) entered a phase in its clinical pipeline, announcing the dosing of the first patient in the Phase 1b multiple ascending dose study of PYC-003.

The investigational RNA-peptide therapy targets autosomal dominant polycystic kidney disease, a debilitating genetic condition characterised by the relentless growth of fluid-filled cysts.

The MAD study is designed to rigorously evaluate the safety and tolerability of repeat dosing while scrutinising critical efficacy markers, such as urinary PC1 protein levels, total kidney volume via MRI, and glomerular filtration rate.

With Phase 1a single ascending dose data anticipated later this year and MAD results expected in 2027, the company is positioning itself for a registrational Phase 2/3 trial and a subsequent new drug application.

The biotech innovator is gaining significant momentum in its ophthalmology portfolio.

At the ARVO 2026 conference in Seattle, PYC presented encouraging interim data for VP-001 and PYC-001, targeting retinitis pigmentosa 11 and autosomal dominant optic atrophy, respectively.

Both candidates continue to demonstrate a robust safety profile, with VP-001 showing "clinically meaningful" improvements in visual acuity.

Supported by a recent $47 million capital raising, PYC’s dual success in renal and ocular medicine underscores its emerging leadership in RNA therapeutics.

At the time of reporting, PYC Therapeutics’ share price was $1.20.